-
A Phase III multi-center double-blind randomized withdrawal study of LCI699 following a 24 week single-arm open-label dose titration and treatment ...
The study aims to confirm the long-term efficacy and safety of LCI699 for the treatment of patients with Cushing's ...
Exact
Phase 
-
An Open Label Study to Assess the Safety and Efficacy of COR-003(2S 4R-Ketoconazole) in the Treatment of Endogenous Cushing ...
The purpose of this clinical research study is to find out if the drug COR-003 is safe and has beneficial ...
Exact
Phase
Showing - of trials